Other News

Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform—and Appointment of Chief Operating Officer

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardio Flow, Inc., a privately held commercial-stage medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), is pleased to announce the successful completion of its first commercial cases for its FreedomFlow® Orbital Atherectomy Platform following FDA clearance in late September. First Commercial Case Performed by the Cardiovascular Institute of the South (CIS) Cardio Flow announced the successful completion

SS Innovations Appoints Dr. Sonia Shokeen as Head of Quality and Regulatory Affairs

Dr. Shokeen brings over 15 years of medical device experience, including time spent at Johnson & Johnson FORT LAUDERDALE, FL, Oct. 30, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making […]

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimen Amended INGLAXA protocol to minimize risk of atypical hemolytic uremic syndrome (aHUS) associated with intravenous (IV) AAV dosing, including addition of R/S immunosuppressive regimen 4D-310 combines a novel, targeted next generation AAV vector (C102) […]

Evident Vascular Announces Scientific Advisory Board and New Board Member

SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors. “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board. Their collective expertise and experience innovating new periph

Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the…

Magenta Medical Reports Positive Results for US Early Feasibility Study of Elevate™ Heart Pump in Providing Temporary Mechanical Circulatory Support During High-Risk PCI Procedures Results presented at TCT 2023 in San Francisco

KADIMA, Israel and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ — The US Early Feasibility Study of Magenta Medical’s Elevate™ System, designed to provide temporary mechanical circulatory support during high-risk percutaneous coronary intervention (HR-PCI) procedures, has successfully met…